Analyst: Eli Lilly considers Alzheimer's submission after phase II

Drug candidate donanemab might potentially become the second Alzheimer's drug to be submitted to the US Food and Drug Administration within a short time span.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Eli Lilly skyrockets following positive Alzheimer's data
For subscribers